Autopsy report · NCT00853762
Atacicept in Multiple Sclerosis Extension Study, Phase II
Cause of deathFutility
“EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\]”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 74 participants enrolled.
- Results were posted on the registry 5 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- EMD Serono
- Sponsor type
- Industry
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Atacicept 25 mg; Atacicept 75 mg; Atacicept 150 mg; Atacicept 150 mg
- Participants
- 74
- Sites
- 47
- Countries
- Australia, Belgium, Canada, Czechia, France, Germany, Lebanon, Lithuania, Netherlands, New Caledonia, Russia, Spain and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.